P654: Analysis of complex four-way BCR-ABL translocations in chronic myeloid leukemia patients and their response to TKI therapy
Abstract
The translocation of the breakpoint cluster region (BCR) gene on chromosome 22 and the Abelson (ABL1) gene on chromosome 9 is a defining feature of Chronic Myeloid Leukemia (CML). This oncogenic gene fusion is located on the altered chromosome 22, commonly referred to as the Philadelphia (Ph) chromosome, and leads to the constitutive activation of ABL1 tyrosine kinase activity. Extensive research has established that tyrosine kinase inhibitors (TKIs), such as Imatinib (Gleevec) and Dasatinib, are effective therapeutic strategies for patients with the classic BCR-ABL1 abnormality.
Fields of Study & Subjects
Chronic Myeloid Leukemia Treatments
Chronic Lymphocytic Leukemia Research
Protein Tyrosine Phosphatases
Publication details
- Journal / source
- Genetics in Medicine Open
- Volume
- 4
- Pages
- 104144–104144
- Publication date
- 1 January 2026
- Language
- EN